Ghana's vaccine revolution: First homemade jab set for 2027 as manufacturing kicks into gear

Ghana is poised to achieve a major milestone in pharmaceutical self-reliance by producing its first domestically manufactured vaccine within the next three years. The tetanus-diphtheria vaccine is expected to roll off production lines by 2027, according to Dr Sodzi Sodzi-Tettey, Chief Executive Officer of the National Vaccine Institute (NVI), who revealed the timeline to Parliament this week.

The ambitious initiative represents a watershed moment for Ghana's healthcare infrastructure, moving the country from complete reliance on imported vaccines towards building a sustainable local manufacturing base. Currently, production materials have already arrived in the country, with active manufacturing processes now underway at Atlantic Lifesciences Limited, the private sector partner driving production efforts on the ground.

How the partnership is making it work

The success of this venture rests on a carefully structured collaboration bringing together multiple stakeholders. The National Vaccine Institute is leading the effort alongside Atlantic Lifesciences Limited, the Noguchi Memorial Institute for Medical Research and PT Bio Farma, an Indonesian pharmaceutical manufacturer. This international partnership model allows Ghana to leverage both local scientific expertise and proven manufacturing capabilities from a regional neighbour with established vaccine production experience.

A critical component of the strategy has been technology transfer. A delegation of Ghanaian experts, including officials from the Food and Drugs Authority (FDA) and private manufacturers, travelled to Indonesia to facilitate knowledge transfer and establish regulatory linkages between the two countries. This groundwork has resulted in a formal technology transfer agreement and unlocked approximately USD 400,000 in direct support from the Indonesian government to fund Ghana's vaccine manufacturing development.

Dr Sodzi-Tettey emphasised that these foundational investments, though they may appear in financial records as workshop or meeting expenses, have proven essential to advancing the project. The regulatory coordination between Ghana's FDA and Indonesian authorities is particularly important, as it ensures that manufacturing processes meet international quality standards from the outset.

Why this matters for Ghana

For a nation spending significant resources on vaccine procurement each year, domestic production capability represents both economic and strategic gains. Moving beyond dependence on imported vaccines strengthens Ghana's healthcare security and reduces foreign currency outflows on essential medicines. The project also signals Ghana's commitment to positioning itself as a pharmaceutical hub within West Africa, potentially opening doors for future regional vaccine supply agreements.

Beyond the immediate tetanus-diphtheria project, the National Vaccine Institute is exploring additional vaccine production opportunities with seed funding pledged by President John Dramani Mahama. This suggests the government views vaccine manufacturing as part of a broader industrial development strategy, not merely a one-off initiative. Successful execution of this first project could pave the way for production of other essential vaccines currently imported.

The initiative also creates technical employment opportunities within Ghana's pharmaceutical and scientific sectors, supporting the development of a specialised workforce in vaccine formulation, quality assurance and regulatory compliance. As the project develops, it may encourage regional partnerships and attract further investment in Ghana's pharmaceutical manufacturing capacity.

If the 2027 target is achieved, Ghana will join a select group of African nations with domestic vaccine manufacturing capability, enhancing the country's credibility in global health discussions and supporting broader continental efforts towards pharmaceutical self-sufficiency.